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mpact of P2Y12 Inhibition by Clopidogrel on
ardiovascular Mortality in Unselected Patients
reated by Percutaneous Coronary Angioplasty
Prospective Registry
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bjectives The aim of this study was to determine whether low platelet response to the P2Y12 re-
eptor antagonist clopidogrel as assessed by Vasodilator-stimulated phosphoprotein ﬂow cytometry
est (VASP- FCT) predicts cardiovascular events in a high-risk population undergoing percutaneous
oronary intervention (PCI).
ackground Impaired platelet responsiveness to clopidogrel is thought to be a determinant of car-
iovascular events after PCI. The platelet VASP-FCT is a new assay speciﬁc to the P2Y12 adenosine
iphosphate receptor-pathway. In this test, platelet activation is expressed as platelet reactivity in-
ex (PRI).
ethods Four-hundred sixty-one unselected patients undergoing urgent (n  346) or planned
n  115) PCI were prospectively enrolled. Patients were classiﬁed as low-response (LR) and re-
ponse (R) to clopidogrel, depending on their PRI. Optimal PRI cutoff was determined by receiver-
perator characteristic curve analysis to 61% (LR: PRI 61% and R: PRI 61%). Follow-up was ob-
ained at a mean of 9  2 months in 453 patients (98.3%).
esults At follow-up, total cardiac mortality rates and possible and total stent thrombosis were
igher in LR patients. Multivariate analysis identiﬁed creatinine clearance (hazard ratio [HR]: 0.95;
5% conﬁdence interval [CI]: 0.93 to 0.98, p  0.001), drug-eluting stent (HR: 5.73; 95% CI: 1.40 to
3.43, p  0.015), C-reactive protein (HR: 1.01; 95% CI: 1.001 to 1.019, p  0.024), and LR to clopi-
ogrel (HR: 4.00; 95% CI: 1.08 to 14.80, p  0.037) as independent predictors of cardiac death. The
eleterious impact of LR to clopidogrel on cardiovascular death was signiﬁcantly higher in patients
mplanted with drug-eluting stent.
onclusions In patients undergoing PCI, LR to clopidogrel assessed by VASP-FCT is an independent
redictor of cardiovascular death at the PRI cutoff value of 61%. The LR clinical impact seems to
e dependent on the type of stent implanted. (J Am Coll Cardiol Intv 2010;3:648–56) © 2010 by
he American College of Cardiology Foundation
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649ombined pharmacological inhibition of the P2Y12 recep-
or by thienopyridines and of the cyclooxygenase pathway by
spirin is currently considered the reference antiplatelet
trategy to prevent thrombotic complication of percutane-
us coronary intervention (PCI) with stent (1,2). Clopi-
ogrel elicits a dose-dependent inhibition of adenosine
iphosphate (ADP)-induced aggregation by specific and
rreversible blockade of the P2Y12 receptor (2). However, a
See page 657
ide interindividual variability in platelet response to clo-
idogrel has been reported (3). The mechanisms for subop-
imal response to clopidogrel are not fully elucidated,
lthough genetic, metabolic, cellular, and clinical factors
ave been proposed as important determinants (1,4–6).
lthough recent data have suggested that residual platelet
ggregability during clopidogrel treatment could portend
orse cardiovascular outcome in patients treated by PCI
7,8), to date no definitive evidence based on hard end
oints has been published. Moreover, although a “low-
esponse” (LR) to clopidogrel might be overcome by dose
itration (9,10), the appropriate test to evaluate the platelet
ffects of clopidogrel and the optimal threshold of respon-
iveness that should be reached remain debatable (11).
Several studies showed that measurement of vasodilator-
timulated phosphoprotein (VASP) phosphorylation might be
mployed for monitoring the effects of thienopyridines on
latelets (10,12–15). Compared with platelet aggregometry,
he VASP assay affords several advantages: 1) specificity of the
2Y12 signaling; 2) no need for a pretreatment measure-
ent; 3) lack of interference with aspirin or glycoprotein
Ib/IIIa antagonists; 4) standardization of the procedure; 5)
easurement on whole blood; and 6) stability of the
easurement up to 48 h (16).
The relationship between VASP phosphorylation and the
ccurrence of clinical cardiovascular events has been evalu-
ted in several studies (12–15). Low response to clopidogrel
as not associated with mortality but with a higher number
f major clinical events (15,17). However these studies
ncluded a relatively low risk population and used different
utoff values to define LR to clopidogrel. In fact, the
ptimal platelet reactivity index (PRI) cutoff for the predic-
ion of cardiovascular events remains undetermined. In the
resent study, we examined whether LR to clopidogrel
ssessed by VASP phosphorylation is an indicator of major
ardiovascular events after PCI.
ethods
atients and design of the prospective registry. Consecutive
atients undergoing PCI between September 2007 and
ecember 2008 in our institution for acute coronary syn-rome (ACS) or stable coronary artery disease were in- iluded. The study was performed in accordance with the
eclaration of Helsinki. Informed written consent was
btained from all patients. The study protocol was approved
y the institutional ethics committee “Comité de Protection
es Personnes EST IV, Strasbourg, France.”
lood samples. Whole blood samples were drawn from
enous punctures at least 6 h after a loading dose (300 or
00 mg) of clopidogrel. Blood was immediately collected
nto a vacutainer tube containing 0.129 mol/l sodium citrate
BD Vacutainer, Becton Dickinson, Sparks, Maryland) and
ent to the hemostasis laboratory (EFS-Alsace, Strasbourg,
rance).
nalysis of VASP phosphorylation
y ﬂow cytometry. The VASP
hosphorylation was assessed with
tandardized flow cytometric assay
Platelet VASP; Diagnostica Stago
Biocytex], Asnières, France) (3).
riefly, a citrated blood sample was
ncubated with prostaglandin E1
PGE1) or with PGE1 and ADP
or 10 min and fixed with parafor-
aldehyde, after which the plate-
ets were permeabilized with non-
onic detergent. The cells were
abeled with a primary monoclo-
al antibody against serine 239-
hosphorylated VASP (16C2),
ollowed by a secondary fluorescein
sothiocyanate-conjugated poly-
lonal goat antimouse antibody.
nalyses were performed on a
ecton Dickinson FACS Calibur
ow cytometer as previously de-
cribed (3). A PRI was calculated
rom the median fluorescence in-
ensity (MFI) of samples incubated
ith PGE1 and ADP according
o the formula: PRI VASP 
[MFI[PGE1]  MFI[PGE1 
DP]/MFI[PGE1])  100. The
RI, expressed as a percentage, is
he difference in VASP fluorescence intensity between resting
PGE1) and activated (ADP) platelets (3).
linical end points. Cardiovascular death was defined as any
eath with demonstrable cardiovascular cause or any death
hat was not clearly attributable to a noncardiovascular
ause. The diagnosis of ST-segment elevation myocardial
nfarction (STEMI) was based on the evidence of a new or
resumably new ST-segment elevation in 2 consecutive
eads and an increase in biochemical markers of myocardial
ecrosis. The diagnosis of non–ST-segment elevation myocar-
ial infarction (NSTEMI) was defined as the occurrence of
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ADP  adenosine
diphosphate
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
LR  low response/
responders (to clopidogrel)
MACE  major adverse
cardiovascular events
MFI  median fluorescence
intensity
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
PGE1  prostaglandin E1
PRI  platelet reactivity
index
R  response/responders
(to clopidogrel)
STEMI  ST-segment
elevation myocardial
infarction
VASP  vasodilator-
stimulated phosphoproteinschemic symptoms, ST-segment depression, and/or T-wave
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650bnormalities and an increase of biochemical markers of
yocardial necrosis. Post-PCI troponin elevation was not
onsidered as recurrent myocardial infarction. Stent throm-
osis was defined according to the Academic Research
onsortium criteria as: definite ACS and angiographic or
athologic evidence of stent thrombosis; probable  unex-
lained death within 30 days or target-vessel infarction
ithout angiographic information; and possible  unex-
lained death after 30 days of stent placement. Major
leeding was defined as intracranial bleeding, life-
hreatening bleeding, or any decrease in hemoglobin requir-
ng transfusion.
Follow-up information was achieved by a written ques-
ionnaire sent to cardiologist and referring physician com-
leted by phone.
tatistical analysis. Continuous variables are expressed as
edian (interquartile range); categorical variables are ex-
ressed as frequencies and percentages. Student t tests have
een used to compare continuous variables between 2
roups. If necessary (i.e., for non-Gaussian distribution),
onparametric Mann-Whitney U test has been used. Chi-
quare test or Fisher exact tests have been used for compar-
son of categorical variables. Continuous variables were
nalyzed for normal distribution with the Shapiro-Wilk
est. Time to event was defined as the time from PCI to the
ate of event, with patients censored at death, loss to
ollow-up, or end of the study (June 30, 2009).
Kaplan-Meier analyses were used to construct survival
lots of time to death after PCI and compared with
og-rank test. Multivariate analysis of survival rates has been
one with Cox models. Variables with p  0.10 in univar-
ate analysis were entered into a stepwise ascending multi-
ariate analysis. The results of the Cox regression are
resented as hazard ratio, 95% confidence intervals (CIs),
nd p values.
The optimal cutoff value for VASP was determined by
sing a receiver-operator characteristic curve analysis based
n the maximal value of the Youden index. A p value 0.05
as considered statistically significant. Statistical analysis
as performed with SPSS version 13.0 software (SPSS,
nc., Chicago, Illinois).
esults
aseline characteristics and biological response to clopidogrel
ssessed by VASP. Four-hundred sixty-one consecutive pa-
ients treated by planned (24.9%) or urgent PCI (75.1%)
ere enrolled. Indication for PCI was STEMI in 151
atients (32.8%), NSTEMI in 154 patients (33.4%), unsta-
le angina in 41 patients (8.9%) and stable angina or silent
schemia in 115 patients (24.9%). The median value of PRI
%) in the cohort was 55 (25th, 75th percentile: 37.78, 70).
atients were assigned in 2 separate groups on the basis of the
RI cutoff value of 61%, which was determined by receiver- (perator characteristic curve analysis (Fig. 1). According to this
utoff, the median value of VASP in the responders (R) group
PRI 61%) was 41.37 (26.8, 51.8) and 73.15 (66.70, 79.08)
n LR group (PRI 61%). Two-hundred and seventy-seven
60.1%) patients had a PRI below 61% and were considered as
, and 184 patients (39.9%) had a PRI equal to or above 61%
nd were considered as LR. Baseline demographic, clinical,
iological, and angiographic characteristics of the 2 groups are
escribed in Tables 1–3. At follow-up (9 2 months), the rate
f dual antiplatelet therapy was equivalent between groups
LR: 85%; R: 87%; p  NS).
eterminants of impaired platelet response to clopidogrel.
he loading dose of clopidogrel was 300 mg in 349 patients
75.7) and 600 mg in 106 patients (23%). Six patients
ere taking long-lasting clopidogrel therapy and did not
eceive any loading dose. The loading dose was similar
etween R and LR groups. The delay that elapsed between
lopidogrel loading dose and VASP measurement was
elow 12 h in 68 patients (14.7%), between 12 and 24 h in
74 patients (37.7%), 24 and 48 h in 70 patients (15.2%), 48
nd 72 h in 61 patients (13.2%), and over 72 h in 88 patients
19.1%). The delay between clopidogrel loading dose and
ASP assay was similar in LR and R; the mean delay was
4 h in both groups.
Of note, LR patients were more frequently obese (52.2% vs.
0.7%, p  0.016) and presented more often with type 2
iabetes mellitus (44.6% vs. 32.1%, p 0.008). No correlation
etween smoking and PRI value could be shown.
mpact of P2Y12 inhibition by clopidogrel on cardiovascular
utcome. Clinical outcomes were available in 453 patients
Figure 1. ROC Curve for the Prediction by PRI% of Cardiac Death
The area under the receiver-operator characteristic (ROC) curve SEM and
the 95% conﬁdence interval are indicated. AUC  area under the curve;
PRI  platelet reactivity index.98.3%), at a mean follow-up of 9  2 months (range 6 to
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6514 months). Follow-up was missing in 8 patients: 6 LR and
R patients.
Death occurred in 26 patients (5.7%), cardiovascular
eath occurred in 20 patients (4.4%), STEMI occurred in 8
atients (1.8%), NSTEMI occurred in 23 patients (5.1%),
nd total stent thrombosis occurred in 24 patients (5.3%).
orty-two patients (9.3%) required target lesion revascular-
zation. Overall, total major adverse cardiovascular events
MACE) rate was 15.7% (71 of 453). At follow-up major
Table 1. Baseline Demographic and Clinical Characteristics
Variable
Total Cohort
(N  461)
Age (yrs) 65.40 (55.8–75.40)
Risk factors/past medical history
Current smoking 228 (49.5)
Hypertension 253 (54.9)
Obesity (BMI 30 kg/m2) 206 (45.3)
Hyperlipidemia 241 (52.3)
Diabetes mellitus type 2 171 (37.1)
Prior STEMI 81 (17.6)
Prior NSTEMI 27 (5.9)
Prior CABG 40 (8.7)
Prior PCI 130 (28.2)
Prior stroke 20 (4.3)
Peripheral vascular disease 32 (6.9)
Chronic renal insufﬁciency 36 (7.8)
Treatment
Aspirin 461 (100)
Clopidogrel 461 (100)
ACE inhibitors 448 (98.5)
Beta-blockers 442 (96.7)
Statin 450 (98.5)
Oral anticoagulants 29 (6.4)
GP IIb/IIIa antagonists 109 (27.6)
PPI 314 (83.7)
Calcium inhibitors 22 (5.1)
Values are n (range) or n (%).
ACE  angiotensin-converting enzyme; BMI  body mass index; CABG  coronary artery byp
percutaneous coronary intervention; PPI proton pomp inhibitor; STEMI ST-segment elevation
Table 2. Angiographic Characteristics
Low Responders
(n  184 )
Responders
(n  277) p Value
LAD 124 (67.4) 192 (69.3) 0.70
CX 76 (41.3) 99 (35.7) 0.24
RCA 104 (56.5) 157 (56.7) 0.99
Left main coronary artery 17 (9.2) 21 (7.6) 0.60
Three-vessel disease 66 (35.9) 73 (26.4) 0.038
Drug-eluting stent 81 (46.3) 128 (48.1) 0.77
Values are n (%).tCX circumflex artery; LAD left anterior descending artery; RCA right coronary artery.leeding occurred in 4 patients: 3 in R patients, and 1 in LR
atients (p  NS). The distribution of major adverse events
n LR and R groups is shown in Table 4. Although no
ifferences in definite or probable stent thrombosis could be
hown between groups, total (definite  probable  possi-
le) and possible stent thrombosis were more frequent in
R patients. Likewise, death was more frequent in LR
atients.
The Kaplan-Meier curves representing cardiovascular
ortality dependent of PRI cutoff of 61% and 50% are
hown, respectively, in Figures 2 and 3. Survival was
ignificantly higher in patients with PRI below 61%. How-
ver by setting the cutoff at 50%, PRI was unable to
iscriminate a higher risk group.
By univariate Cox analysis (Table 5), Killip class III to
V, drug-eluting stent (DES), renal dysfunction, and LR to
lopidogrel, defined as a PRI above or equal to 61% were
ssociated with total death. Killip class III to IV, DES, renal
ysfunction, C-reactive protein, and LR to clopidogrel
efined as a PRI above or equal to 61%, were significantly
elated to cardiac death. Three-vessel disease, DES implan-
ow Responders
(n  184)
Responders
(n  277) p Value
3.95 (54.62–73.28) 66.25 (57.52–75.90) 0.16
83 (45.1) 145 (52.3) 0.13
104 (56.5) 149 (53.8) 0.57
95 (52.2) 111 (40.7) 0.016
100 (54.3) 141 (50.9) 0.51
82 (44.6) 89 (32.1) 0.008
31 (16.8) 50 (18.1) 0.80
14 (7.6) 13 (4.7) 0.23
14 (7.6) 26 (9.4) 0.61
53 (28.8) 77 (27.8) 0.83
7 (3.8) 13 (4.7) 0.82
15 (8.2) 17 (6.1) 0.46
18 (9.8) 18 (6.5) 0.22
184 (100) 277 (100) 1
184 (100) 277 (100) 1
178 (97.8) 270 (98.9) 0.45
175 (95.6) 267 (97.4) 0.30
180 (98.4) 270 (98.5) 1
15 (8.3) 14 (5.1) 0.24
58 (36.9) 51 (21.4) 0.001
121 (80.1) 193 (86.2) 0.15
9 (5.2) 13 (5) 1
t surgery; GP  glycoprotein; NSTEMI  non–ST-segment elevation myocardial infarction; PCI 
dial infarction.L
6
ass grafation, and unstable angina were associated with MACE.
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652s expected, patients implanted with at least 1 DES were
ore frequently diabetic, underwent more frequently
lanned PCI, were more frequently treated for LAD lesion,
nd received longer stents (data not shown).
Multivariate Cox regression analysis identified LR to
lopidogrel (PRI 61%), DES, renal dysfunction, and
-reactive protein as independent predictors of cardiac
eath (Table 6). Cardiac death was higher in LR patients
reated with DES in comparison with R patients treated
ith DES and bare-metal stent (BMS)-treated patients
egardless of platelet response (LR or R) (Fig. 4).
Table 3. Biological Characteristics
Low Responders
(n  184)
Responders
(n  277) p Value
Glycemia (g/l) 1.30 (1.06–1.70) 1.13 (0.97–1.53) 0.004
HbA1C (%) 6.3 (5.8–7.5) 6.2 (5.60–7.30) 0.150
Creatinine (mol/l) 92 (74.7–114.25) 85 (70.57–105.55) 0.034
Tn admission (g/l) 0.41 (0.14–1.81) 0.21 (0.08–0.78) 0.008
Tn H6 (g/l) 2.89 (0.20–25.71) 0.70 (0.14–5.67) 0.008
Tn peak (g/l) 12.18 (1.41–49.06) 5.24 (0.43–25.03) 0.018
CPK (U/l) 209 (89–505) 135 (80.5–308) 0.028
BNP (ng/l) 103 (47.3–266.50) 142 (52–328) 0.197
CRP (mg/l) 7 (4–24.30) 5.65 (4–16.63) 0.057
WBC (109/l) 9.28 (7.21–11.30) 8.58 (7.10–11.28) 0.341
Hb (g/dl) 13.5 (12.2–14.65) 13.4 (12–14.60) 0.374
Platelets (109/l) 244 (188–293) 240.5 (195.3–285) 0.944
Total cholesterol (g/l) 1.77 (1.49–2.15) 1.67 (1.37–2.07) 0.171
LDLc (g/l) 1.10 (0.76–1.44) 1.03 (0.76–1.34) 0.534
HDLc (g/l) 0.40 (0.30–0.40) 0.40 (0.30–0.50) 0.162
TG (g/l) 1.27 (0.92–1.85) 1.16 (0.79–1.64) 0.045
PRI (%) 73.15 (66.70–79.08) 41.37 (26.8–51.8) 0.0001
Values are n (range).
BNP brain natriuretic peptide; CPK creatinine phosphokinase; CRP C-reactive protein;
HbHemoglobin; HDLc high-density lipoprotein cholesterol; LDLc low-density lipoprotein
cholesterol; PRI platelet reactivity index; TG triglycerides; Tn troponin; Tn H6 troponin
6 h after admission; WBCwhite blood cells.
Table 4. MACE at Follow-Up
Total
Cohort
(n  453)
Low
Responders
(n  178)
Responders
(n  275)
p
Value
Total death 26 (5.7) 17 (9.6) 9 (3.3) 0.005
Cardiac death 20 (4.4) 14 (7.9) 6 (2.2) 0.004
STEMI 8 (1.8) 3 (1.7) 5 (1.8) 1.00
NSTEMI 23 (5.1) 11 (6.2) 12 (4.4) 0.39
TLR 42 (9.3) 18 (10.1) 24 (8.7) 0.62
Deﬁnite stent thrombosis 9 (2) 5 (2.8) 4 (1.5) 0.49
Probable stent thrombosis 8 (1.8) 5 (2.8) 3 (1.1) 0.27
Possible stent thrombosis 7 (1.5) 6 (3.3) 1 (0.4) 0.017
All stent thrombosis 24 (5.3) 15 (8.3) 9 (3.3) 0.018
MACE 71 (15.7) 35 (19.7) 22 (13.1) 0.06
Values are n (%). The follow-up was available in 453 of 461 patients.
MACE  major adverse cardiovascular events; TLR  target lesion revascularization; otherabbreviations as in Table 1.iscussion
he data from this prospective registry suggest that LR to
lopidogrel identified by VASP phosphorylation analysis in
high-risk population is indicative of increased cardiovas-
ular mortality after PCI. Our results underline the rele-
Figure 2. Kaplan-Meier Analysis for the Probability of Cardiac Survival
According to the PRI 61% Threshold
Blue line  patients with platelet reactivity index (PRI) 61%; green line 
patients with PRI 61%. Abbreviations as in Figure 1.
Figure 3. Kaplan-Meier Analysis for the Probability of Cardiac Survival
According to the PRI 50% Threshold
Blue line  patients with platelet reactivity index (PRI) 50%; green line 
patients with PRI 50%. Abbreviations as in Figure 1.
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653ance of the 61% threshold for PRI to identify patients at
igher risk of cardiovascular mortality and total stent
hrombosis. The deleterious impact of LR to clopidogrel on
ardiovascular outcome seems higher in patients treated
ith DES. Finally, LR to clopidogrel seems to be associated
ith diabetes mellitus and obesity.
onitoring of the P2Y12 inhibition by clopidogrel: value of
ASP assay. Clopidogrel effect depends on the generation
f active metabolites to achieve a degree of blockade of the
2Y12 receptor that substantially blunts the extent of
2Y12-mediated amplification of platelet stimulation. The
epatic conversion of clopidogrel in active metabolites
nvolves the enzymatic activities of several P450 cyto-
Table 5. Univariate Analysis for Prediction of Cardiac Death, Total Death, a
Variable
Cardiac Death
HR (95% CI) p Value
Age 1.02 (0.98–1.06) 0.29
Sex 1.97 (0.81–4.83) 0.14
Diabetes mellitus 2.16 (0.89–5.24) 0.09
Obesity 1.25 (0.52–3.0) 0.62
Hypertension 0.81 (0.34–1.94) 0.63
Dyslipidemia 0.48 (0.19–1.91) 0.11
Smoking 0.86 (0.35–2.07) 0.73
History of stroke 1.47 (0.20–11.03) 0.71
History of STEMI 1.16 (0.39–3.46) 0.79
History of NSTEMI 2.82 (0.83–9.62) 0.098
STEMI 1.41 (0.58–3.45) 0.45
NSTEMI 1.35 (0.55–3.30) 0.51
Unstable angina 1.83 (0.54–6.27) 0.33
Stable angina 0.03 (0.00–2.11) 0.11
Killip III to IV 9.21 (3.67–23.14) 0.0001
Three-vessel disease 1.24 (0.50–3.12) 0.64
LAD 1.80 (0.60–5.38) 0.29
DES 4.81 (1.59–14.61) 0.006
Stent length 30 mm 1.65 (0.22–12.33) 0.63
Creatinine clearance (ml/min) 0.96 (0.94–0.98) 0.001
CRP 1.008 (1.0–1.025) 0.033
PRI 61% 3.65 (1.40–9.50) 0.008
PRI 50% 2.22 (0.80–6.12) 0.12
PRI 69% 2.42 (1.00–5.85) 0.049
CI confidence interval; DES drug-eluting stent(s); HR hazard ratio; other abbreviations as in T
Table 6. Multivariate Analysis for Cardiac Death Prediction
Variable Cardiac Death p Value
DES 5.73 (1.40–23.43) 0.015
Creatinine clearance 0.95 (0.93–0.98) 0.001
CRP 1.01 (1.001–1.019) 0.024
PRI 61% 4.00 (1.08–14.80) 0.037
Values are hazard ratio (95% confidence interval).Abbreviations as in Tables 3 and 5.Figure 4. Kaplan-Meier Analysis of Cardiac Survival With Respect to
Platelet Responsiveness to Clopidogrel and Stent Type
BMS  bare-metal stent(s); DES  drug-eluting stent(s); PRI  plateletnd MACE
Total Death MACE
HR (95% CI) p Value HR (95% CI) p Value
1.02 (0.98–1.05) 0.30 1.01 (0.99–1.03) 0.38
1.78 (0.78–4.06) 0.17 0.98 (0.57–1.67) 0.94
1.83 (0.82–4.10) 0.14 1.38 (0.86–2.21) 0.19
1.27 (0.57–2.83) 0.56 1.02 (0.64–1.63) 0.94
0.59 (0.26–1.32) 0.20 0.92 (0.58–1.47) 0.74
0.63 (0.28–1.43) 0.27 0.65 (0.40–1.04) 0.07
0.75 (0.33–1.69) 0.49 1.36 (0.85–2.17) 0.20
1.18 (1.16–8.77) 0.87 1.90 (0.69–5.22) 0.22
0.94 (0.32–2.74) 0.90 0.77 (0.40–1.52) 0.46
2.22 (0.66–7.47) 0.20 1.41 (0.61–3.27) 0.42
1.49 (0.66–3.35) 0.34 1.37 (0.85–2.21) 0.19
1.46 (0.65–3.29) 0.36 0.87 (0.52–1.45) 0.59
1.54 (0.46–5.21) 0.48 1.99 (1.02–3.91) 0.045
0.03 (0.001–1.44) 0.08 0.43 (0.22–0.84) 0.014
9.16 (3.88–26.63) 0.0001 3.06 (1.56–5.97) 0.001
0.97 (0.40–2.35) 0.95 1.66 (1.03–2.66) 0.037
1.38 (0.55–3.47) 0.50 1.23 (0.73–0.73) 0.44
3.16 (1.27–7.86) 0.01 1.65 (1.02–2.68) 0.043
1.33 (0.18–9.86) 0.78 1.94 (0.70–5.33) 0.20
0.97 (0.95–0.98) 0.001 0.99 (0.98–1.00) 0.31
1.007 (1.001–1.015) 0.059 1.004 (0.10–1.01) 0.12
2.71 (1.18–6.20) 0.02 1.54 (0.97–2.46) 0.07
1.86 (0.77–4.51) 0.17 1.36 (0.83–2.22) 0.22
1.85 (0.80–4.24) 0.15 1.14 (0.67–1.92) 0.64reactivity index.
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654hromes (4,6). Among them, the CYP2C19 has an impor-
ant role. Indeed, the carriage of at least 1 copy of the
YP2C19*2 allele was recently associated with decreased
oncentrations of active metabolite (18) and was shown to
reatly increase the risk of adverse thrombotic events in
oung survivors of acute myocardial infarction (4). Al-
hough the concept of “genotyping” seems somewhat ap-
ealing, it is difficult to translate it into clinical practice,
ecause the results of such assessment would be unlikely to
e available during the early high thrombotic risk period
fter ACS. In addition, the possible impact of the redun-
ancy described among the cytochromes deserves further
larification, and the impact of CYP2C19 on the metabo-
ism of more potent thienopyridines such as prasugrel might
e limited (18). Another approach is to directly measure the
ctive metabolite concentrations in the plasma, but this
emains technically challenging. Consequently, a more suit-
ble approach to assess biological response to clopidogrel is
o provide a pharmacodynamic assessment of P2Y12 path-
ay blockade (16). Platelet aggregometry presents several
imitations, including but not limited to: 1) wide interindi-
idual variability of the response to ADP and subsequent
arge overlap between clopidogrel-treated and -untreated
atients; 2) lack of specificity for the P2Y12 pathway; 3) the
eed for a large sample volume; 4) the complexity of the
re-analytic phase; and 5) the wide variability of the results
mong laboratories (7,8,16). For these reasons, the VASP
hosphorylation assay is considered the gold standard to
onitor thienopyridines therapy.
mpact of P2Y12 inhibition by clopidogrel on cardiovascular
utcome. Several studies have recently highlighted the del-
terious impact of LR to clopidogrel on stent thrombosis
13,14), post-stent ischemic events (7), and peri-procedural
nfarction (8). These studies have been performed in differ-
nt subgroups of patients undergoing PCI, including pa-
ients with STEMI or NSTEMI and patients undergoing
lective PCI. In the present work, total death and cardio-
ascular death occurred in 5.7% and 4.4% of patients,
espectively. These mortality rates were higher than those
eported in the study by Bonello et al. (17) (2.7% and 2.1%,
espectively). However, it should be emphasized that the
atter study had enrolled lower-risk patients (34% stable
ngina, 40% silent ischemia, and 26% low-risk NSTEMI).
y comparison, our study population was mainly ACS
atients (32.8% STEMI, 33.4% NSTEMI). The rates of
ardiovascular events reported in the present work are in line
ith those of a recent meta-analysis (19). Moreover, the
ortality rate among patients with LR to clopidogrel is in
ccordance with a recent publication by Marcucci et al. (20).
he impact of the use of different methodologies in the
valuation of clopidogrel effect on platelet function deserves
urther investigation. In a recent study, Paniccia et al. (21)
eported a strong correlation between platelet aggregometry
nd the VerifyNow cartridge but only weak correlation wetween VASP-related PRI value and values obtained by
he VerifyNow assay. These 2 tests do not measure the same
hing: light transmission aggregometry as well as the auto-
ated VerifyNow device measure the global aggregatory
esponse of platelets stimulated by ADP. The latter inte-
rates numerous factors, including receptor activation, in-
racellular signaling, integrin activation, and platelet secre-
ion. In contrast, the VASP phosphorylation assay only
easures the P2Y12 responsiveness to ADP on a very
roximal signaling event (16).
ASP threshold for the prediction of cardiovascular events. In
ur study, the analysis of receiver-operator characteristic
urve for the prediction of cardiac mortality with the VASP
ssay determined an optimal PRI cutoff of 61%. Briefly,
2Y12 inhibition by clopidogrel follows a Gaussian distri-
ution; the “biological” threshold was defined in our lab as
he mean PRI value minus 2 SD in patients untreated by
lopidogrel. According to this biological definition, almost
0% of patients receiving clopidogrel standard regimen
300 mg/75 mg) treatment were undistinguishable from
ntreated patients (3). The optimal PRI threshold is still a
atter of debate, with regard to the “biological threshold
PRI: 69%)” (3) in comparison with the “clinical efficacy
hreshold” (14). Barragan et al. (14) first reported, in a
etrospective study, that a PRI value higher than 50% might
e indicative of subacute stent thrombosis. In a pragmatic
nd empiric approach, the threshold of “clinical” efficacy was
herefore set at 50%. The clinical relevance of this cutoff was
ater confirmed in a prospective study according to a very
igh negative predictive value for MACE prediction after
CI (17). Moreover, Blindt et al. (15) observed that a PRI
alue above 48% was the only independent predictor of stent
hrombosis in high-risk PCI. In rats, Schumacher et al. (22)
howed that a 50% PRI value corresponded to a nearly 90%
2Y12 receptor blockage. However, in the present work, the
0% cutoff was not predictive of total or cardiac mortality
fter PCI, whereas the threshold of 69% was slightly
ssociated with cardiovascular mortality. At follow-up, the
1% cutoff was indicative of both total and cardiac mortality
s well as possible and total stent thrombosis. Overall, our
tudy validates for the first time the usefulness of the VASP
ssay after PCI to predict hard end points.
mpact of LR to clopidogrel in patients treated with DES on
ardiovascular outcome. In our registry, the implantation of
ES was associated with an increased risk of total death and
ardiac death at 9-month follow-up. Interestingly, the
eleterious impact of LR to clopidogrel on cardiovascular
utcome seems higher in patients treated with DES. This
esult should be taken with great caution, given the inherent
imitation of registry data, the limited size of the cohort, and
he possible contribution of unmeasured confounding fac-
ors. Of note, increased mortality with DES as compared
ith BMS has already been reported in very large nation-
ide registries (23,24). Our result is also consistent with a
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655ecent report by Trenk et al. (5). In this study, LR to
lopidogrel was particularly deleterious in patients treated
ith DES (5). One might hypothesize that the behavior of
atients with LR to clopidogrel is comparable to the
ehavior of untreated patients. In the large Duke registry,
isenstein et al. (25) observed that patients with DES under
lopidogrel treatment at 12 months have a lower rate of
eath at 24 months. This relationship between long-term
lopidogrel treatment and long-term death was not ob-
erved among patient with BMS (25). Likewise, the cessa-
ion of clopidogrel treatment in patients with DES is
ssociated with increased death and MACE at 6-, 12-, and
ven 24-month follow-up (26). These findings support the
iew that the delayed endothelium healing after DES
equires a more robust and sustained platelet inhibition than
fter BMS placement (5). Altogether, these data strongly
uggest that the evaluation of platelet responsiveness to
lopidogrel could be useful for the management of patients
reated with DES.
mpact of diabetes mellitus and obesity on P2Y12 pathway
lockade. We observed a significantly higher proportion of
iabetic and obese patients among the LR group. Low
esponsiveness to antiplatelet drugs has already been re-
orted in diabetic persons (27), and the mechanism for this
emains poorly understood. Possible hypotheses include the
ollowing: 1) nonenzymatic glycation of platelet membrane
roteins that might alter receptor functions and/or signaling
athways; 2) overexpression of platelet integrins such as
lycoprotein IIb/IIIa; 3) increased thromboxane A2 synthesis;
) decreased nitric oxide and antioxidant production;
) disturbed calcium homeostasis; 6) impairment of platelet
nhibition by insulin, through P2Y12 pathway, due to insulin
esistance; and 7) increased fibrinogen levels (27,28). An-
iolillo et al. (29) showed that patients with diabetes exhibit
igher platelet reactivity and reduced sensitivity to clopi-
ogrel. Moreover, high platelet reactivity in diabetic pa-
ients taking dual antiplatelet therapy was associated with a
igher risk of long-term adverse cardiovascular events. In
greement with their finding, we found a higher proportion
f LR among diabetic patients. Some authors have sug-
ested that low platelet response to thienopyridines ob-
erved in diabetic patients could mainly result in lower levels
f circulating active metabolites, whereas ex vivo, the extent
f platelet inhibition by thienopyridines was shown to be
omparable in type 2 diabetes mellitus and nondiabetic
atients (30).
In agreement with previous works, our study confirms
hat obesity is associated with lower platelet response to
lopidogrel (8,28,31). The relationship between obesity and
R to clopidogrel is complex and might be related to
nsufficient dosage of drug or adipose tissue-induced inflam-
ation. Our data are also in line with the observation in the
RITON–TIMI 38 study (TRial to Assess Improvementn Therapeutic Outcomes by Optimizing Platelet Inhibi-ioN with Prasugrel–Thrombolysis In Myocardial Infarc-
ion 38), in which low body mass index was associated with
ore bleeding complications. Relative overdosing of anti-
hrombotic medications together with higher platelet inhi-
ition activation observed in lean patients were proposed to
xplain this adverse outcome (32).
tudy limitations. Single time point laboratory assessment
epresents a common limitation to most studies assessing
he prognostic implication of platelet function. In addition,
he timing of the VASP analysis was not fully homoge-
eous. The VASP testing was not compared with other
echniques of platelet function. The potential impact of
igher doses of clopidogrel has not been investigated in LR
atients. We could not exclude that a disproportionate
oncompliance to clopidogrel in the LR group could have
mpaired the cardiovascular outcome. The adjudication of
ardiovascular events was not realized by an independent
ommittee. However, this adjudication was realized by 2
hysicians not aware of the PRI values. Given the relatively
ow number of cardiovascular deaths (20), the interpretation
f the multivariate analysis including 4 variables should be
nterpreted with caution. As with similar evaluation of
egistry data, there are inherent limitations mainly with
nown or unknown confounding factors.
onclusions
he results of the present prospective registry suggest that
ow responsiveness to clopidogrel, assessed by flow cytomet-
ic VASP phosphorylation defined as a PRI 61%, is an
ndependent predictor of all-cause mortality, cardiovascular
eath, and possible and total stent thrombosis after PCI.
he impact of LR to clopidogrel was particularly deleterious
n patients treated with DES.
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